Jack Khattar - Supernus Pharmaceuticals Founder, CEO and President and Director
| SUPN Stock | USD 35.82 0.30 0.83% |
CEO
Mr. Jack A. Khattar is President, Chief Executive Officer, Secretary, Director of the company. He is the founder of our Company and has served as our President, Chief Executive Officer and Secretary and a Director since 2005. From 1999 to 2005, Mr. Khattar served in various positions during that time as a board member, President and Chief Executive Officer of Shire Laboratories Inc., the drug delivery subsidiary of Shire plc. From 1999 to 2004, he also served as a member of Shire plc executive committee. Prior to that, Mr. Khattar served as an executive officer and the chairman of the management committee at CIMA Labs Inc., a drug delivery company where he was also responsible for business development, corporate alliances and strategic planning. Prior to joining CIMA in 1995, Mr. Khattar held several marketing and business development positions at Merck Co., Novartis, Playtex and Kodak in various locations, including the United States, Europe and the Middle East. Mr. Khattar served on the board of Rockville Economic Development, Inc. from 2003 until 2013. He currently serves on the board of directors of Prevacus, Inc., a privatelyheld development stage biotechnology company, and on the advisory board of New Rhein Healthcare, a private equity firm. Mr. Khattar also serves as Chairman of the board of directors of scPharmaceuticals, a publicly traded pharmaceutical company. Mr. Khattar earned his degrees in Marketing with a BBA from American University of Beirut and an MBA from the Wharton School of the University of Pennsylvania. Mr. Khattar leadership, executive, managerial, business and pharmaceutical company experience, along with his more than 30 years of industry experience in the development and commercialization of pharmaceutical products and drug delivery technologies, qualify him to be a director. since 2005.
| Age | 63 |
| Tenure | 19 years |
| Professional Marks | MBA |
| Address | 9715 Key West Avenue, Rockville, MD, United States, 20850 |
| Phone | 301 838 2500 |
| Web | https://www.supernus.com |
Jack Khattar Latest Insider Activity
Tracking and analyzing the buying and selling activities of Jack Khattar against Supernus Pharmaceuticals stock is an integral part of due diligence when investing in Supernus Pharmaceuticals. Jack Khattar insider activity provides valuable insight into whether Supernus Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Supernus Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Supernus Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Jack Khattar over two weeks ago Disposition of 125000 shares by Jack Khattar of Supernus Pharmaceuticals at 9.13 subject to Rule 16b-3 | ||
Jack Khattar over two months ago Disposition of 21000 shares by Jack Khattar of Supernus Pharmaceuticals subject to Rule 16b-3 | ||
Jack Khattar over two months ago Acquisition by Jack Khattar of 21000 shares of Supernus Pharmaceuticals subject to Rule 16b-3 | ||
Jack Khattar over six months ago Acquisition by Jack Khattar of 17300 shares of Scpharmaceuticals at 11.71 subject to Rule 16b-3 |
Supernus Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.0289 % which means that it generated a profit of $0.0289 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0622 %, meaning that it created $0.0622 on every $100 dollars invested by stockholders. Supernus Pharmaceuticals' management efficiency ratios could be used to measure how well Supernus Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Supernus Pharmaceuticals' Return On Tangible Assets are very stable compared to the past year. As of the 22nd of November 2024, Return On Assets is likely to grow to 0, while Return On Capital Employed is likely to drop (0.01). At this time, Supernus Pharmaceuticals' Debt To Assets are very stable compared to the past year. As of the 22nd of November 2024, Fixed Asset Turnover is likely to grow to 22.16, while Total Assets are likely to drop about 676.1 M.Similar Executives
| Found 9 records | CEO Age | ||
| Frank Lee | Pacira BioSciences, | 56 | |
| Vikram Karnani | Collegium Pharmaceutical | 49 | |
| Mario DPHIL | Evotec SE ADR | 61 | |
| MARC KIKUCHI | Dr Reddys Laboratories | 51 | |
| Patrick Aghanian | Dr Reddys Laboratories | 55 | |
| Milan Kalawadia | Dr Reddys Laboratories | N/A | |
| M Ramana | Dr Reddys Laboratories | 52 | |
| Venkata MBA | Dr Reddys Laboratories | 55 | |
| Nikhil Lalwani | ANI Pharmaceuticals | 46 | |
Management Performance
| Return On Equity | 0.0622 | ||||
| Return On Asset | 0.0289 |
Supernus Pharmaceuticals Leadership Team
Elected by the shareholders, the Supernus Pharmaceuticals' board of directors comprises two types of representatives: Supernus Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Supernus. The board's role is to monitor Supernus Pharmaceuticals' management team and ensure that shareholders' interests are well served. Supernus Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Supernus Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Padmanabh Bhatt, Chief Scientific Officer and Sr. VP of Intellectual Property | ||
| Timothy Dec, Senior CFO | ||
| Tami Martin, VP Affairs | ||
| Jeff Bozick, Senior Chain | ||
| Kevin Esq, Compliance Officer | ||
| Taylor Raiford, Senior Sales | ||
| Bryan Roecklein, Senior Development | ||
| Jonathan Rubin, VP Officer | ||
| Todd MBA, Commercial Marketing | ||
| MBA MD, Senior Officer | ||
| MD MBA, Senior Officer | ||
| Jack Khattar, Founder, CEO and President and Director | ||
| Kevin Anderson, Compliance Officer | ||
| RN Esq, Senior Affairs | ||
| Frank Mottola, GMP Quality | ||
| Jack MBA, President Founder |
Supernus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Supernus Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0622 | ||||
| Return On Asset | 0.0289 | ||||
| Profit Margin | 0.09 % | ||||
| Operating Margin | 0.16 % | ||||
| Current Valuation | 1.63 B | ||||
| Shares Outstanding | 55.22 M | ||||
| Shares Owned By Insiders | 5.01 % | ||||
| Shares Owned By Institutions | 94.99 % | ||||
| Number Of Shares Shorted | 6.8 M | ||||
| Price To Earning | 15.25 X |
Pair Trading with Supernus Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Supernus Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Supernus Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Supernus Stock
| 0.73 | TIL | Instil Bio | PairCorr |
| 0.68 | PFE | Pfizer Inc Fiscal Year End 4th of February 2025 | PairCorr |
| 0.66 | ME | 23Andme Holding | PairCorr |
| 0.64 | INZY | Inozyme Pharma | PairCorr |
| 0.61 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
The ability to find closely correlated positions to Supernus Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Supernus Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Supernus Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Supernus Pharmaceuticals to buy it.
The correlation of Supernus Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Supernus Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Supernus Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Supernus Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Supernus Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Supernus Pharmaceuticals. If investors know Supernus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Supernus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.99) | Earnings Share 1.07 | Revenue Per Share 11.877 | Quarterly Revenue Growth 0.142 | Return On Assets 0.0289 |
The market value of Supernus Pharmaceuticals is measured differently than its book value, which is the value of Supernus that is recorded on the company's balance sheet. Investors also form their own opinion of Supernus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Supernus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Supernus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Supernus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Supernus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Supernus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Supernus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.